Sutro Biopharma (STRO) EBT Margin (2017 - 2025)
Historic EBT Margin for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to 586.58%.
- Sutro Biopharma's EBT Margin fell 139600.0% to 586.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 216.92%, marking a year-over-year decrease of 1462600.0%. This contributed to the annual value of 362.81% for FY2024, which is 3051800.0% down from last year.
- Latest data reveals that Sutro Biopharma reported EBT Margin of 586.58% as of Q3 2025, which was down 139600.0% from 18.07% recorded in Q2 2025.
- In the past 5 years, Sutro Biopharma's EBT Margin registered a high of 41.22% during Q4 2023, and its lowest value of 1146.05% during Q1 2025.
- Over the past 5 years, Sutro Biopharma's median EBT Margin value was 362.83% (recorded in 2021), while the average stood at 348.17%.
- In the last 5 years, Sutro Biopharma's EBT Margin surged by 4419800bps in 2023 and then crashed by -6985400bps in 2025.
- Over the past 5 years, Sutro Biopharma's EBT Margin (Quarter) stood at 357.85% in 2021, then decreased by -12bps to 400.76% in 2022, then soared by 110bps to 41.22% in 2023, then crashed by -1248bps to 473.28% in 2024, then fell by -24bps to 586.58% in 2025.
- Its EBT Margin stands at 586.58% for Q3 2025, versus 18.07% for Q2 2025 and 1146.05% for Q1 2025.